Title:
PEGYLATED RAPAMYCIN COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/206796
Kind Code:
A1
Abstract:
Disclosed are PEGylated rapamycin compound, and a preparation method therefor and the use thereof. The PEGylated rapamycin compound is represented by formula (I), wherein n is 10-150. The preparation method comprises: dissolving mPEG-COOH in an organic solvent, adding a catalyst EDC.HCl, DMAP and RAPA, and carrying out a stirring reaction at 10-40℃ in a dark place. The PEGylated rapamycin compound and the pharmaceutical preparation thereof can be used in the preparation of a drug for reducing immune response, can effectively inhibit the generation of anti-drug antibodies of biological drugs such as urate oxidase, and are suitable for being prepared into nano-drugs.
Inventors:
GUO SHENGRONG (CN)
SHEN YUANYUAN (CN)
SHEN YUANYUAN (CN)
Application Number:
PCT/CN2022/083907
Publication Date:
October 06, 2022
Filing Date:
March 30, 2022
Export Citation:
Assignee:
HANGZHOU YISHENG PHARMACEUTICAL TECH DEVELOPMENT CO LTD (CN)
SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN)
SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN)
International Classes:
A61K47/50; A61K47/60; A61K47/61; C08G65/333
Domestic Patent References:
| WO2018053434A1 | 2018-03-22 |
Foreign References:
| CN104689330A | 2015-06-10 | |||
| CN110314236A | 2019-10-11 | |||
| CN104448295A | 2015-03-25 |
Other References:
NATURE NANOTECHNOLOGY, vol. 11, no. 10, 2016, pages 890 - 899
Attorney, Agent or Firm:
SHANGHAI HANGSOME INTELLECTUAL PROPERTY LTD (CN)
Download PDF:
Previous Patent: A CYCLIN-DEPENDENT KINASE INHIBITOR
Next Patent: EGFR INHIBITOR, AND COMPOSITION AND USE THEREOF
Next Patent: EGFR INHIBITOR, AND COMPOSITION AND USE THEREOF